Cerny Erich H, Cerny Thomas
Chilka Ltd, 13 Cours des Bastions, 1205 Geneva, Switzerland.
Expert Opin Investig Drugs. 2008 May;17(5):691-6. doi: 10.1517/13543784.17.5.691.
Three different companies have completed Phase II clinical studies of their anti-nicotine vaccines and are rushing to obtain regulatory approval and to bring their vaccine candidates to the market. The vaccines are composed of the nicotine molecule linked to a carrier protein and an adjuvant. The results in all three clinical studies are encouraging. Preliminary results seem to indicate that subjects with high anti-nicotine antibody levels demonstrate high quit rates and that the vaccines appear to be compatible with and complementary to approved forms of smoking cessation therapies. The data available do not yet allow us to give definitive results for long-term quit rates. We expect the vaccines to appear on the market during a time window between 2009 and 2011.
三家不同的公司已经完成了其抗尼古丁疫苗的二期临床研究，正急于获得监管批准并将其候选疫苗推向市场。这些疫苗由与载体蛋白和佐剂相连的尼古丁分子组成。所有三项临床研究的结果都令人鼓舞。初步结果似乎表明，抗尼古丁抗体水平高的受试者戒烟率也高，而且这些疫苗似乎与已获批的戒烟疗法兼容且互补。现有数据还无法让我们得出长期戒烟率的确切结果。我们预计这些疫苗将在2009年至2011年的某个时间段上市。
